In a communication during the Annual Meeting of the Society for Immunotherapy BerGen Bio announces that the company’s drug candidate Bemcentinib meets the primary endpoint in first cohort of Phase II NSCLC study in combination with Keytruda®. The primary efficacy endpoint requires that at least 25% evaluable patients achieve a clinical response when treated with the novel drug combination, defined as either complete or partial response, as measured by Response Evaluation Criteria in Solid Tumors (RECIST).

A secondary endpoint of median Progression Free Survival (mPFS) reported significant 3-fold improvement in AXL positive vs negative patients, as defined by BerGenBio’s composite AXL tumor-immune score.


Read more